<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;ff=20250108220823&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;ff=20250108220823&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 09 Jan 2025 03:08:24 +0000</lastbuilddate>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Deep learning for cardiac abnormalities in chest X-rays: performance metrics with imbalanced data and extracardiac objects</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39776179/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250108220823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae759. doi: 10.1093/eurheartj/ehae759. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39776179/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250108220823&v=2.18.0.post9+e462414">39776179</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae759>10.1093/eurheartj/ehae759</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39776179</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Eisuke Kagawa</dc:creator>
<dc:creator>Masaya Kato</dc:creator>
<dc:creator>Keigo Dote</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Deep learning for cardiac abnormalities in chest X-rays: performance metrics with imbalanced data and extracardiac objects</dc:title>
<dc:identifier>pmid:39776179</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae759</dc:identifier>
</item>
<item>
<title>Giant left atrial appendage aneurysm: a source of multiple thrombotic events despite medical therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39776175/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250108220823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae935. doi: 10.1093/eurheartj/ehae935. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39776175/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250108220823&v=2.18.0.post9+e462414">39776175</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae935>10.1093/eurheartj/ehae935</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39776175</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Jacopo Lin</dc:creator>
<dc:creator>Francesco Maisano</dc:creator>
<dc:creator>Michele De Bonis</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Giant left atrial appendage aneurysm: a source of multiple thrombotic events despite medical therapy</dc:title>
<dc:identifier>pmid:39776175</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae935</dc:identifier>
</item>
<item>
<title>Coffee drinking timing and mortality in US adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39776171/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250108220823&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Drinking coffee in the morning may be more strongly associated with a lower risk of mortality than drinking coffee later in the day.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae871. doi: 10.1093/eurheartj/ehae871. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: To identify the patterns of coffee drinking timing in the US population and evaluate their associations with all-cause and cause-specific mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This study included 40 725 adults from the National Health and Nutrition Examination Survey 1999-2018 who had complete information on dietary data and 1463 adults from the Women's and Men's Lifestyle Validation Study who had complete data on 7-day dietary record. Clustering analysis was used to identify patterns of coffee drinking timing.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In this observational study, two distinct patterns of coffee drinking timing [morning type (36% of participants) and all-day-type patterns (14% of participants)] were identified in the National Health and Nutrition Examination Survey and were validated in the Women's and Men's Lifestyle Validation Study. During a median (interquartile range) follow-up of 9.8 (9.1) years, a total of 4295 all-cause deaths, 1268 cardiovascular disease deaths, and 934 cancer deaths were recorded. After adjustment for caffeinated and decaffeinated coffee intake amounts, sleep hours, and other confounders, the morning-type pattern, rather than the all-day-type pattern, was significantly associated with lower risks of all-cause (hazard ratio: .84; 95% confidential interval: .74-.95) and cardiovascular disease-specific (hazard ratio: .69; 95% confidential interval: .55-.87) mortality as compared with non-coffee drinking. Coffee drinking timing significantly modified the association between coffee intake amounts and all-cause mortality (P-interaction = .031); higher coffee intake amounts were significantly associated with a lower risk of all-cause mortality in participants with morning-type pattern but not in those with all-day-type pattern.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Drinking coffee in the morning may be more strongly associated with a lower risk of mortality than drinking coffee later in the day.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39776171/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250108220823&v=2.18.0.post9+e462414">39776171</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae871>10.1093/eurheartj/ehae871</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39776171</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Xuan Wang</dc:creator>
<dc:creator>Hao Ma</dc:creator>
<dc:creator>Qi Sun</dc:creator>
<dc:creator>Jun Li</dc:creator>
<dc:creator>Yoriko Heianza</dc:creator>
<dc:creator>Rob M Van Dam</dc:creator>
<dc:creator>Frank B Hu</dc:creator>
<dc:creator>Eric Rimm</dc:creator>
<dc:creator>JoAnn E Manson</dc:creator>
<dc:creator>Lu Qi</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Coffee drinking timing and mortality in US adults</dc:title>
<dc:identifier>pmid:39776171</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae871</dc:identifier>
</item>
<item>
<title>Start your day with a morning coffee!</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39776142/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250108220823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae823. doi: 10.1093/eurheartj/ehae823. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39776142/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250108220823&v=2.18.0.post9+e462414">39776142</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae823>10.1093/eurheartj/ehae823</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39776142</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Thomas F Lüscher</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Start your day with a morning coffee!</dc:title>
<dc:identifier>pmid:39776142</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae823</dc:identifier>
</item>
<item>
<title>Efficacy of aggressive lipid-lowering therapy on plaque stabilization in femoropopliteal disease, assessed using near-infrared spectroscopy intravascular ultrasound</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39776140/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250108220823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae900. doi: 10.1093/eurheartj/ehae900. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39776140/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250108220823&v=2.18.0.post9+e462414">39776140</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae900>10.1093/eurheartj/ehae900</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39776140</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Yusuke Sato</dc:creator>
<dc:creator>Tetsuji Morishita</dc:creator>
<dc:creator>Hiroshi Tada</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Efficacy of aggressive lipid-lowering therapy on plaque stabilization in femoropopliteal disease, assessed using near-infrared spectroscopy intravascular ultrasound</dc:title>
<dc:identifier>pmid:39776140</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae900</dc:identifier>
</item>
<item>
<title>Combustible cigarette smoking harms nearly every organ in the body</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39775792/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250108220823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae896. doi: 10.1093/eurheartj/ehae896. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39775792/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250108220823&v=2.18.0.post9+e462414">39775792</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae896>10.1093/eurheartj/ehae896</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39775792</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Danbee Kang</dc:creator>
<dc:creator>Ki Hong Choi</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Combustible cigarette smoking harms nearly every organ in the body</dc:title>
<dc:identifier>pmid:39775792</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae896</dc:identifier>
</item>
<item>
<title>Novel technology, novel challenges: How do we compare the performance of artificial intelligence to human experts?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39775785/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250108220823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae760. doi: 10.1093/eurheartj/ehae760. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39775785/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250108220823&v=2.18.0.post9+e462414">39775785</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae760>10.1093/eurheartj/ehae760</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39775785</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Pierre Elias</dc:creator>
<dc:creator>Shreyas Bhave</dc:creator>
<dc:creator>Timothy Joseph Poterucha</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Novel technology, novel challenges: How do we compare the performance of artificial intelligence to human experts?</dc:title>
<dc:identifier>pmid:39775785</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae760</dc:identifier>
</item>
<item>
<title>Genius and the CVD Polypill-A Step Toward Achieving Health Equity?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39775777/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250108220823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 8. doi: 10.1001/jamacardio.2024.4820. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39775777/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250108220823&v=2.18.0.post9+e462414">39775777</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4820>10.1001/jamacardio.2024.4820</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39775777</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Genius and the CVD Polypill-A Step Toward Achieving Health Equity?</dc:title>
<dc:identifier>pmid:39775777</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4820</dc:identifier>
</item>
<item>
<title>Cost-Effectiveness of a Polypill for Cardiovascular Disease Prevention in an Underserved Population</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39775718/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250108220823&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results of this economic evaluation suggest that polypill treatment could be a high value intervention for a low-income, majority Black population with limited access to health care services. It could additionally reduce health disparities.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 8. doi: 10.1001/jamacardio.2024.4812. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The Southern Community Cohort Study (SCCS) Polypill Trial showed that a cardiovascular polypill (a single pill containing a statin and 3 half-standard dose antihypertensive medications) effectively controls cardiovascular disease (CVD) risk factors in a majority Black race and low-income population. The cost-effectiveness of polypill treatment in this population has not been previously studied.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine the cost-effectiveness of the cardiovascular polypill.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: A discrete-event simulation version of the well-established CVD policy model simulated clinical and economic outcomes of the SCCS Polypill Trial from a health care sector perspective. A time horizon of 10 years was adopted. Polypill treatment was priced at $463 per year in the base-case analysis. Model input data were derived from the National Health and Nutrition Examination Survey, Medical Expenditure Panel Survey, pooled longitudinal cohort studies, the SCCS Polypill Trial, and published literature. Two cohorts were analyzed: an SCCS Polypill Trial-representative cohort of 100 000 individuals and all trial-eligible non-Hispanic Black US adults. Study parameters and model inputs were varied extensively in 1-way and probabilistic sensitivity analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Polypill treatment or usual care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURES: Primary outcomes were direct health care costs (US dollar 2023) and quality-adjusted life-years (QALYs), both discounted 3% annually, and the incremental cost per QALY gained.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the trial-representative cohort of 100 000 individuals (mean [SD] age, 56.9 [5.9] years; 61 807 female [61.8%]), polypill treatment was projected to yield a mean of 1190 (95% uncertainty interval, 287-2159) additional QALYs compared with usual care, at a cost of approximately $10 152 000. Hence, polypill treatment was estimated to cost $8560 per QALY gained compared with usual care and was high value (&lt;$50 000 per QALY gained) in 99% of simulations. Polypill treatment was estimated to be high value when priced at $559 or less per year and cost saving when priced at $443 or less per year. In almost all sensitivity analyses, polypill treatment remained high value. In a secondary analysis of 3 602 427 trial-eligible non-Hispanic Black US adults (mean [SD] age, 55.4 [7.6] years; 2 006 597 female [55.7%]), polypill treatment was high value, with an estimated cost of $13 400 per QALY gained.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this economic evaluation suggest that polypill treatment could be a high value intervention for a low-income, majority Black population with limited access to health care services. It could additionally reduce health disparities.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39775718/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250108220823&v=2.18.0.post9+e462414">39775718</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4812>10.1001/jamacardio.2024.4812</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39775718</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Ciaran N Kohli-Lynch</dc:creator>
<dc:creator>Andrew E Moran</dc:creator>
<dc:creator>Dhruv S Kazi</dc:creator>
<dc:creator>Kirsten Bibbins-Domingo</dc:creator>
<dc:creator>Neil Jordan</dc:creator>
<dc:creator>Dustin French</dc:creator>
<dc:creator>Yiyi Zhang</dc:creator>
<dc:creator>Thomas J Wang</dc:creator>
<dc:creator>Brandon K Bellows</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Cost-Effectiveness of a Polypill for Cardiovascular Disease Prevention in an Underserved Population</dc:title>
<dc:identifier>pmid:39775718</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4812</dc:identifier>
</item>
<item>
<title>Recurrent Chest Pain in a Young Female Patient With Family History of Cancer</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39774791/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250108220823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 8. doi: 10.1001/jamacardio.2024.4823. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39774791/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250108220823&v=2.18.0.post9+e462414">39774791</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4823>10.1001/jamacardio.2024.4823</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39774791</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Ushasi Saraswati</dc:creator>
<dc:creator>Jaideep Singh Bhalla</dc:creator>
<dc:creator>Allan L Klein</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Recurrent Chest Pain in a Young Female Patient With Family History of Cancer</dc:title>
<dc:identifier>pmid:39774791</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4823</dc:identifier>
</item>
<item>
<title>What truly drives the significant reduction in major adverse cardiac events after switching to electronic cigarettes following percutaneous coronary intervention?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39774636/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250108220823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae895. doi: 10.1093/eurheartj/ehae895. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39774636/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250108220823&v=2.18.0.post9+e462414">39774636</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae895>10.1093/eurheartj/ehae895</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39774636</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Yuqin Zhao</dc:creator>
<dc:creator>Jun Sun</dc:creator>
<dc:creator>Xiaolei Lv</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>What truly drives the significant reduction in major adverse cardiac events after switching to electronic cigarettes following percutaneous coronary intervention?</dc:title>
<dc:identifier>pmid:39774636</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae895</dc:identifier>
</item>
<item>
<title>Myxoedema coma and myxoedema heart disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39774628/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250108220823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae937. doi: 10.1093/eurheartj/ehae937. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39774628/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250108220823&v=2.18.0.post9+e462414">39774628</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae937>10.1093/eurheartj/ehae937</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39774628</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Philip Haaf</dc:creator>
<dc:creator>Julia Beck</dc:creator>
<dc:creator>Michael Mayr</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Myxoedema coma and myxoedema heart disease</dc:title>
<dc:identifier>pmid:39774628</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae937</dc:identifier>
</item>
<item>
<title>Omitting Aspirin in High-Risk Left Ventricular Assist Device Implant</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39774623/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250108220823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 8. doi: 10.1001/jamacardio.2024.4861. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39774623/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250108220823&v=2.18.0.post9+e462414">39774623</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4861>10.1001/jamacardio.2024.4861</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39774623</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Nosheen Reza</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Omitting Aspirin in High-Risk Left Ventricular Assist Device Implant</dc:title>
<dc:identifier>pmid:39774623</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4861</dc:identifier>
</item>
<item>
<title>Aspirin and Hemocompatibility After LVAD Implantation in Patients With Atherosclerotic Vascular Disease: A Secondary Analysis From the ARIES-HM3 Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39774588/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250108220823&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results of this prespecified analysis of the ARIES-HM3 randomized clinical trial demonstrate that in patients with advanced heart failure who have classical indications for antiplatelet therapy use at the time of LVAD implantation, aspirin avoidance was safe and not associated with increased thrombosis risk. Importantly, elimination of aspirin was associated with no increased thrombosis but a reduction in nonsurgical bleeding events in patients with a history of PCI,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 8. doi: 10.1001/jamacardio.2024.4849. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure (ARIES-HM3) study demonstrated that aspirin may be safely eliminated from the antithrombotic regimen after HeartMate 3 (HM3 [Abbott Cardiovascular]) left ventricular assist device (LVAD) implantation. This prespecified analysis explored whether conditions requiring aspirin (prior percutaneous coronary intervention [PCI], coronary artery bypass grafting [CABG], stroke, or peripheral vascular disease [PVD]) would influence outcomes differentially with aspirin avoidance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To analyze aspirin avoidance on hemocompatibility-related adverse events (HRAEs) at 1 year after implant in patients with a history of CABG, PCI, stroke, or PVD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was an international, multicenter, prospective, double-blind, placebo-controlled, randomized clinical trial including patients implanted with a de novo HM3 LVAD across 51 centers. Data analysis was conducted from April to July 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Patients were randomized in a 1:1 ratio to receive aspirin (100 mg per day) or placebo, in addition to a vitamin K antagonist (VKA) targeted to an international normalized ratio of 2 to 3 in both groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Primary end point (assessed for noninferiority) was a composite of survival free of any nonsurgical (>;14 days after implant) HRAEs including stroke, pump thrombosis, bleeding, and arterial peripheral thromboembolism at 12 months. Secondary end points included nonsurgical bleeding, stroke, and pump thrombosis events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 589 of 628 patients (mean [SD] age, 57.1 [13.7] years; 456 male [77.4%]) who contributed to the primary end point analysis, a history of PCI, CABG, stroke, or PVD was present in 41% (240 of 589 patients). There was no interaction between the presence of an atherosclerotic vascular condition and effect of aspirin compared with placebo (P for interaction= .23). The preset 10% noninferiority margin was not crossed for the studied subgroup of patients. Thrombotic events were rare, with no differences between aspirin and placebo in patients with and without vascular disease (P for interaction = .77). Aspirin treatment was associated with a higher rate of nonsurgical major bleeding events in the group with prior vascular condition history compared with those without aspirin (rate ratio for placebo compared with aspirin, 0.52; 95% CI, 0.35-0.79).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this prespecified analysis of the ARIES-HM3 randomized clinical trial demonstrate that in patients with advanced heart failure who have classical indications for antiplatelet therapy use at the time of LVAD implantation, aspirin avoidance was safe and not associated with increased thrombosis risk. Importantly, elimination of aspirin was associated with no increased thrombosis but a reduction in nonsurgical bleeding events in patients with a history of PCI, CABG, stroke, or PVD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04069156.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39774588/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250108220823&v=2.18.0.post9+e462414">39774588</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4849>10.1001/jamacardio.2024.4849</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39774588</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Finn Gustafsson</dc:creator>
<dc:creator>Nir Uriel</dc:creator>
<dc:creator>Ivan Netuka</dc:creator>
<dc:creator>Jason N Katz</dc:creator>
<dc:creator>Francis D Pagani</dc:creator>
<dc:creator>Jean M Connors</dc:creator>
<dc:creator>Ulrich P Jorde</dc:creator>
<dc:creator>Daniel Zimpfer</dc:creator>
<dc:creator>Yuriy Pya</dc:creator>
<dc:creator>Jennifer Conway</dc:creator>
<dc:creator>Anelechi Anyanwu</dc:creator>
<dc:creator>Anna Mara Scandroglio</dc:creator>
<dc:creator>Nasir Sulemanjee</dc:creator>
<dc:creator>Pavan Atluri</dc:creator>
<dc:creator>Mary Keebler</dc:creator>
<dc:creator>Craig H Selzman</dc:creator>
<dc:creator>Jeffrey D Alexis</dc:creator>
<dc:creator>Christopher Hayward</dc:creator>
<dc:creator>John Henderson</dc:creator>
<dc:creator>Nicholas Dirckx</dc:creator>
<dc:creator>Carlo Gazzola</dc:creator>
<dc:creator>Mandeep R Mehra</dc:creator>
<dc:creator>ARIES Investigators</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Aspirin and Hemocompatibility After LVAD Implantation in Patients With Atherosclerotic Vascular Disease: A Secondary Analysis From the ARIES-HM3 Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39774588</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4849</dc:identifier>
</item>
<item>
<title>Error in Table</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39774571/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250108220823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 8. doi: 10.1001/jamacardio.2024.5456. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39774571/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250108220823&v=2.18.0.post9+e462414">39774571</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5456>10.1001/jamacardio.2024.5456</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39774571</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:date>2025-01-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Error in Table</dc:title>
<dc:identifier>pmid:39774571</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5456</dc:identifier>
</item>
<item>
<title>Errors in Author Affiliations and Open Access Updated</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39774481/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250108220823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 1;10(1):102. doi: 10.1001/jamacardio.2024.4934.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39774481/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250108220823&v=2.18.0.post9+e462414">39774481</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4934>10.1001/jamacardio.2024.4934</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39774481</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:date>2025-01-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Errors in Author Affiliations and Open Access Updated</dc:title>
<dc:identifier>pmid:39774481</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4934</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39774480/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250108220823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 1;10(1):4. doi: 10.1001/jamacardio.2024.3405.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39774480/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250108220823&v=2.18.0.post9+e462414">39774480</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3405>10.1001/jamacardio.2024.3405</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39774480</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:date>2025-01-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:39774480</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3405</dc:identifier>
</item>
<item>
<title>X-Chromosome-Linked miRNAs Regulate Sex Differences in Cardiac Physiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39772608/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250108220823&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These data highlight the importance of sex-differential miRNA mechanisms in mediating sex-specific functions and their potential relevance to human cardiac diseases.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Dec 30. doi: 10.1161/CIRCRESAHA.124.325447. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Males and females exhibit distinct anatomic and functional characteristics of the heart, predisposing them to specific disease states.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We identified microRNA (miRNAs/miR) with sex-differential expression in mouse hearts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Four conserved miRNAs are present in a single locus on the X-chromosome and are expressed at higher levels in females than males. We show miRNA, miR-871, is responsible for decreased expression of the protein SRL (sarcalumenin) in females. SRL is involved in calcium signaling, and we show it contributes to differences in electrophysiology between males and females. miR-871 overexpression mimics the effects of the cardiac physiology of conditional cardiomyocyte-specific Srl-null mice. Inhibiting miR-871 with an antagomir in females shortened ventricular repolarization. The human orthologue of miR-871, miR-888, coevolved with the SRL 3' untranslated region and regulates human SRL.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These data highlight the importance of sex-differential miRNA mechanisms in mediating sex-specific functions and their potential relevance to human cardiac diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39772608/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250108220823&v=2.18.0.post9+e462414">39772608</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325447>10.1161/CIRCRESAHA.124.325447</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39772608</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>James I Emerson</dc:creator>
<dc:creator>Wei Shi</dc:creator>
<dc:creator>Jose Paredes-Larios</dc:creator>
<dc:creator>William G Walker</dc:creator>
<dc:creator>Josiah E Hutton</dc:creator>
<dc:creator>Ileana M Cristea</dc:creator>
<dc:creator>William F Marzluff</dc:creator>
<dc:creator>Frank L Conlon</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>X-Chromosome-Linked miRNAs Regulate Sex Differences in Cardiac Physiology</dc:title>
<dc:identifier>pmid:39772608</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325447</dc:identifier>
</item>
<item>
<title>Off TARGET Effects in Stent Comparison Trials: Looking Beyond the Primary Endpoint Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39772371/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250108220823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 16:S0735-1097(24)10508-6. doi: 10.1016/j.jacc.2024.11.021. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39772371/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250108220823&v=2.18.0.post9+e462414">39772371</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.021>10.1016/j.jacc.2024.11.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39772371</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Daniel O'Callaghan</dc:creator>
<dc:creator>J J Coughlan</dc:creator>
<dc:creator>Daniele Giacoppo</dc:creator>
<dc:creator>Roisin Colleran</dc:creator>
<dc:creator>Robert A Byrne</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Off TARGET Effects in Stent Comparison Trials: Looking Beyond the Primary Endpoint Analysis</dc:title>
<dc:identifier>pmid:39772371</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.021</dc:identifier>
</item>
<item>
<title>Efficacy of ICD Electrogram-Guided Sustained Monomorphic VT Ablation: Discerning Fact From Fiction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39772370/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250108220823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 23:S0735-1097(24)10522-0. doi: 10.1016/j.jacc.2024.11.028. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39772370/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250108220823&v=2.18.0.post9+e462414">39772370</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.028>10.1016/j.jacc.2024.11.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39772370</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Sanghamitra Mohanty</dc:creator>
<dc:creator>John D Burkhardt</dc:creator>
<dc:creator>Vincenzo Mirco La Fazia</dc:creator>
<dc:creator>Andrea Natale</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Efficacy of ICD Electrogram-Guided Sustained Monomorphic VT Ablation: Discerning Fact From Fiction</dc:title>
<dc:identifier>pmid:39772370</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.028</dc:identifier>
</item>
<item>
<title>Outcomes for Children With Congenital Heart Disease Undergoing Ventricular Assist Device Implantation: An ACTION Registry Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39772369/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250108220823&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: CHD patients are more likely in extremis at VAD implantation and experience higher rates of adverse events and worse survival compared to those with non-CHD. Timely referral for patients with CHD experiencing worsening heart failure and a proactive approach to VAD implantation has the potential to improve outcomes for this vulnerable cohort.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 19:S0735-1097(24)10047-2. doi: 10.1016/j.jacc.2024.10.083. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: There are no contemporary reports that highlight the national outcomes for children with congenital heart disease (CHD) undergoing ventricular assist device (VAD) implantation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to evaluate differences in VAD outcomes for children with CHD to those with non-CHD as well as those with univentricular CHD to those with biventricular CHD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Data for CHD and non-CHD patients from the multicenter ACTION (Advanced Cardiac Therapies Improving Outcomes Network) undergoing VAD implantation from April 2018 to February 2023 were included. Preimplantation characteristics were compared between CHD and non-CHD as well as univentricular and biventricular CHD patients. Postimplantation survival and adverse events were compared between these cohorts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 966 patients undergoing VAD implantation, 352 (36%) had CHD, the majority of whom had univentricular CHD (230; 65%). Compared to non-CHD, CHD patients were younger (median age: 1.2 vs 9.4 years), were listed as INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) 1 (36.1% vs 28.7%), were on mechanical ventilation (67.0% vs 44.1%), received total parenteral nutrition (63.6% vs 45.1%), and were on extracorporeal membrane oxygenation (ECMO) preimplantation (33.2% vs 20.5%) (P &lt; 0.05 for all). Except for lower estimated glomerular filtration rate in children with univentricular CHD (median: 47.3 vs 59.9 mL/min/1.73 m<sup>2</sup>), there were no significant differences in clinical characteristics in univentricular vs biventricular CHD patients. Children with CHD compared to non-CHD were more likely to experience major adverse events (stroke, bleeding, infection, respiratory failure, renal and hepatic dysfunction) and have worse adjusted survival (HR: 2.05; 95% CI: 1.39-3.02; P &lt; 0.001). There were no differences in adjusted survival in univentricular vs biventricular CHD (P >; 0.05).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: CHD patients are more likely in extremis at VAD implantation and experience higher rates of adverse events and worse survival compared to those with non-CHD. Timely referral for patients with CHD experiencing worsening heart failure and a proactive approach to VAD implantation has the potential to improve outcomes for this vulnerable cohort.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39772369/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250108220823&v=2.18.0.post9+e462414">39772369</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.083>10.1016/j.jacc.2024.10.083</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39772369</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Shahnawaz Amdani</dc:creator>
<dc:creator>Muhammad Farrukh Shezad</dc:creator>
<dc:creator>Benjamin Kroslowitz</dc:creator>
<dc:creator>Madeleine Townsend</dc:creator>
<dc:creator>Anna Joong</dc:creator>
<dc:creator>Hani Najm</dc:creator>
<dc:creator>Bradley S Marino</dc:creator>
<dc:creator>David N Rosenthal</dc:creator>
<dc:creator>Angela Lorts</dc:creator>
<dc:creator>Matthew J O'Connor</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Outcomes for Children With Congenital Heart Disease Undergoing Ventricular Assist Device Implantation: An ACTION Registry Analysis</dc:title>
<dc:identifier>pmid:39772369</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.083</dc:identifier>
</item>





























</channel>
</rss>